液体活检MRD在肺癌中的应用及探讨  

Application and exploration of liquid biopsy MRD in lung cancer

作　　者：郑杰 何勇 ZHENG Jie;HE Yong(Department of Respiratory and Critical Care Medicine,Army Special Medical Center,Chongqing 400042,China)

机构地区：[1]陆军特色医学中心呼吸与危重症医学科,重庆400042

出　　处：《重庆医学》2024年第6期801-804,共4页Chongqing medicine

基　　金：重庆市技术创新与应用发展专项乡村振兴项目(estc2021jscx-xczxX0015)。

摘　　要：近年来,液体活检技术取得实质性进展,尤其是循环肿瘤DNA(ctDNA)在指导癌症患者个性化治疗和全程管理中发挥了重要作用。随着检测技术灵敏度、精准度的提高,微小残留病灶(MRD)检测为癌症患者的复发预测、病情监控及精准治疗提供了新的可能。该文关注了液体活检MRD在早期、局部晚期和晚期肺癌患者中的临床应用与研究进展,并讨论了肺癌MRD检测的前景与挑战。Recent years have seen significant advancements in liquid biopsy techniques,especially in the use of circulating tumor DNA(ctDNA),guiding personalized treatment and comprehensive management of cancer patients.Improvements in detection techniques,specifically in sensitivity and precision,have opened up new possibilities for monitoring minimal residual disease(MRD),predicting relapse and refining treatment strategies.This paper will focus on the clinical application and research advancements of MRD in liquid biopsies for early,locally advanced,and advanced lung cancer patients,while also looking towards future prospects and potential challenges in lung cancer MRD detection.

关 键 词：肺癌 液体活检 微小残留病灶 免疫治疗 靶向治疗 

分 类 号：R734.2[医药卫生—肿瘤]